S. M. Mangsbo
www.farmbio.uu.se
0000-0002-1355-2678
Uppsala University
75 papers found
Refreshing results…
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice
Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations
MALT1 inhibition suppresses antigen-specific T cell responses
Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS‐COV‐2 Antibodies
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines
Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells
Missing publications? Search for publications with a matching author name.